natgillin/translations-raw huggingface dataset:
• Severe inflammation/eruption of the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis)
• hudo vnetje/izbruh izpuščajev na koži in sluznici (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza)
For treatment of metastatic breast cancer, Pazenir is usually given once every three weeks (on day 1 of a 21-day cycle).
Pri metastatskem raku dojk se zdravilo Pazenir navadno daje enkrat na tri tedne (1. dan 21-dnevnega cikla).
Albumin is known to mediate endothelial caveolar transcytosis of plasma constituents, and in vitro studies demonstrated that the presence of albumin enhances transport of paclitaxel across endothelial cells.
Znano je, da albumin posreduje endotelijsko kaveolarno transcitozo sestavin plazme; in vitro raziskave pa so pokazale, da prisotnost albumina izboljša transport paklitaksela preko endotelijskih celic.
• Pain and swelling in the nose, skin infections, infection due to catheter line
• bolečine in otekline v nosu, kožna okužba, okužba zaradi katetra
Your doctor will arrange a pregnancy test before starting treatment with Pazenir.
Zdravnik bo uredil, da boste pred začetkom zdravljenja z zdravilom Pazenir opravili test nosečnosti.
After first reconstitution, the dispersion should be filled into an infusion bag immediately.
Po prvi rekonstituciji je treba disperzijo takoj napolniti v infuzijsko vrečo.
No additional dosage reductions, other than those for all patients, are recommended for patients 65 years and older.
Za bolnike, stare 65 let in več, ne priporočajo dodatnih zmanjševanj odmerjanja, poleg tistih, ki so priporočljiva za vse bolnike.
• Abnormal decrease in the number of types of white blood cells (neutrophils, lymphocytes or leukocytes) in the blood
• nenormalno znižanje števila določenih vrst belih krvnih celic (nevtrofilcev, limfocitov ali levkocitov) v krvi
Take care and speak to your doctor when taking Pazenir at the same time as any of the following:
Bodite pozorni in se posvetujte z zdravnikom, če jemljete zdravilo Pazenir skupaj s katerimi od naslednjih zdravil:
Neurotoxicity to paclitaxel was evaluated through improvement by one grade for patients experiencing Grade 3 peripheral neuropathy at any time during therapy.
Nevrotoksičnost zaradi paklitaksela so vrednotili na osnovi izboljšanja za eno stopnjo pri bolnikih s periferno nevropatijo 3. stopnje kadarkoli med zdravljenjem.
Table 2: Dose modifications for neutropenia and/or thrombocytopenia at the start of a cycle or within a cycle for patients with pancreatic adenocarcinoma Cycle Day
Preglednica 2: Prilagajanje odmerka pri nevtropeniji in/ali trombocitopeniji v začetku cikla ali med ciklom pri bolnikih z adenokarcinomom trebušne slinavke Dan cikla
The solution should be directed onto the inside wall of the vial.
Raztopino usmerite proti notranji steni viale.
Pazenir will be given to you by a doctor or nurse into a vein from an intravenous drip.
Zdravilo Pazenir vam bo dal zdravnik ali medicinska sestra v veno, z intravensko kanilo.
Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation.
Mehanizem delovanja Paklitaksel je antimikrotubulno sredstvo, ki pospešuje sestavljanje mikrotubulov iz dimerov tubulina in jih stabilizira s preprečevanjem njihove depolimerizacije.
The safety and efficacy of human serum albumin-paclitaxel nanoparticles in children and adolescents aged 0-17 years has not been established.
Varnost in učinkovitost paklitaksela, vezanega na nanodelce humanega serumskega albumina, pri otrocih in mladostnikih, starih 0-17 let, nista bili dokazani.
Table 13: Non-inferiority analyses on progression-free survival and overall survival in randomized non-small cell lung cancer trial (intent-to-treat population)
Preglednica 13: Ne-inferiornostne analize preživetja brez napredovanja bolezni in celokupnega preživetja v randomiziranem preskušanju nedrobnoceličnega pljučnega raka (populacija z namenom zdravljenja)
Treatment effects on OS favoured the human serum albumin-paclitaxel nanoparticles/gemcitabine arm across the majority of pre-specified subgroups (including gender, KPS, geographic region, primary location of pancreatic cancer, stage at diagnosis, presence of liver metastases, presence of peritoneal carcinomatosis, prior Whipple procedure, presence of biliary stent at baseline, presence of pulmonary metastases, and number of metastatic sites).
Učinki zdravljenja na celokupno preživetje so bili ugodnejši v skupini s paklitakselom, vezanim na nanodelce humanega serumskega albumina/gemcitabinom v večini vnaprej določenih podskupin (ki so vključevale spol, KPS, zemljepisno območje, primarno lokacijo raka trebušne slinavke, stadij ob diagnozi, prisotnost metastaz v jetrih, prisotnost peritonealne karcinomatoze, predhodni Whipplov postopek, prisotnost biliarnega stenta v izhodišču, prisotnost pljučnih metastaz in število lokacij z metastazami).
The exact total dosing volume of 5 mg/ml dispersion required for the patient should be calculated and the appropriate amount of reconstituted Pazenir should be injected into an empty, sterile, PVC or non-PVC type intravenous bag.
Izračunati je treba natančen celokupen volumen odmerka 5 mg/ml disperzije, ki ga potrebuje bolnik, nato pa ustrezno količino rekonstituiranega zdravila Pazenir injicirati v prazno, sterilno intravensko vrečo polivinilkloridnega (PVC) ali ne-polivinilkloridnega tipa.
1On Day 1 of the 21-day cycle reduce the dose of Pazenir and carboplatin simultaneously.
1 1. dan 21-dnevnega cikla zmanjšajte odmerek zdravila Pazenir in karboplatina sočasno.
Pazenir is an albumin-bound nanoparticle formulation of paclitaxel, which may have substantially different pharmacological properties compared to other formulations of paclitaxel (see sections 5.1 and 5.2).
Zdravilo Pazenir je oblika paklitaksela, vezanega na albuminske nanodelce, ki ima lahko bistveno drugačne farmakološke lastnosti kot druge formulacije paklitaksela (glejte poglavji 5.1 in 5.2).
Based on the published literature, in vitro studies of binding to human serum proteins, (using paclitaxel at concentrations ranging from 0.1 to 50 µg/ml), indicate that the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.
Kot je navedeno v objavljeni literaturi, in vitro raziskave o vezavi na beljakovine humanega seruma (ob uporabi paklitaksela v koncentracijah, ki so segale od 0,1 do 50 µg/ml), kažejo, da prisotnost cimetidina, ranitidina, deksametazona ali difenhidramina ni vplivala na vezavo paklitaksela na beljakovine.
Pazenir is supplied as a sterile lyophilised powder for reconstitution before use.
Pazenir se dobavlja kot sterilen liofiliziran prašek za rekonstitucijo pred uporabo.
The second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63 patients with metastatic breast cancer.
Pri drugi raziskavi so uporabili odmerek 300 mg/m2 kot 30-minutno infuzijo pri 63 bolnikih z metastatskim rakom dojk.
The majority of alopecia events occurred less than one month after initiation of human serum albumin-paclitaxel nanoparticles.
Večina primerov alopecije se je pojavila manj kot en mesec po uvedbi paklitaksela, vezanega na nanodelce humanega serumskega albumina.
SMQ = Standardized MedDRA Query; SMQ is a grouping of several MedDRA preferred terms to capture a medical concept.
SMQ = standardizirana MedDRA poizvedba (Standardized MedDRA Query); SMQ je grupiranje več MedDRA preferenčnih izrazov, s katerimi se zajame medicinski pojem.
Inspect the dispersion in the vial for particulate matter.
Preglejte disperzijo v viali glede vidnih delcev.
In the very elderly (≥75 years) who received Pazenir and gemcitabine, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation including haematologic toxicities, peripheral neuropathy, decreased appetite and dehydration.
Pri zelo starih bolnikih (≥ 75 let), ki so prejemali zdravilo Pazenir in gemcitabin, je bila zvečana incidenca resnih neželenih učinkov in neželenih učinkov, ki so povzročili prekinitev zdravljenja, med drugim hematoloških toksičnosti, periferne nevropatije, zmanjšanega apetita in dehidracije.
However, based on the published literature, paclitaxel is a potentially carcinogenic and genotoxic agent at clinical doses, based upon its pharmacodynamic mechanism of action.
Z ozirom na objavljeno literaturo pa je paklitaksel potencialno kancerogen in genotoksičen v kliničnih odmerkih, glede na farmakodinamični mehanizem delovanja.
There are very limited data on the use of paclitaxel in human pregnancy.
Podatkov o uporabi paklitaksela med nosečnostjo pri ljudeh je malo.
The occurrence of Grade 1 or 2 sensory neuropathy does not generally require dose reduction.
Ob pojavu senzorične nevropatije 1. ali 2. stopnje, odmerka navadno ni treba zmanjšati.
Upon diagnosis of cystoid macular oedema, treatment with Pazenir should be discontinued.
Po diagnosticiranem cistoidnem makularnem edemu je treba zdravljenje z zdravilom Pazenir ukiniti.
The solution should not be injected directly onto the powder as this will result in foaming.
Raztopine ne injicirajte neposredno na prašek, saj bi tako prišlo do penjenja.
If not used immediately, the dispersion may be stored in a refrigerator (2°C-8°C) for up to 24 hours in the vial when kept in the outer carton in order to protect it from light.
Če je ne uporabite takoj, jo lahko shranite v hladilniku (2 °C-8 °C) do 24 ur, če je v viali in zunanji ovojnini za zagotovitev zaščite pred svetlobo.
• Pazenir is used in metastatic breast cancer when at least one other therapy has been tried but has not worked and you are unsuitable for treatments containing a group of medicines called “anthracyclines”.
• Zdravilo Pazenir se uporablja pri metastatskem raku dojk, kadar je bila uporabljena vsaj ena drugačna oblika zdravljenja, ki pa ni bila uspešna, zdravljenje z drugimi zdravili, ki vsebujejo skupino zdravil, imenovano "antraciklini", pa za vas ni primerno.
Mild to moderate renal impairment (creatinine clearance ≥30 to <90 ml/min) has no clinically important effect on the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel.
Blaga do zmerna okvara ledvic (očistek kreatinina ≥ 30 do < 90 ml/min) ni klinično pomembno vplivala na največjo hitrost izločanja paklitaksela in sistemsko izpostavljenost paklitakselu (AUC in Cmax).
Of the patients with treatment interrupted due to peripheral neuropathy, 44% (31/70 patients) were able to resume human serum albumin-paclitaxel nanoparticlesat a reduced dose.
Od bolnikov, pri katerih je bilo zdravljenje prekinjeno zaradi periferne nevropatije, jih je lahko 44 % (31 od 70 bolnikov) nadaljevalo s prejemanjem paklitaksela, vezanega na nanodelce humanega serumskega albumina, v zmanjšanem odmerku.
• medicines used to help you lower blood lipid levels (e.g. gemfibrozil)
• zdravila, ki pomagajo znižati raven lipidov v krvi (npr. gemfibrozil)
At the clinical dose range of 80 to 300 mg/m2, the mean plasma clearance of paclitaxel ranges from 13 to 30 L/h/m2, and the mean terminal half-life ranges from 13 to 27 hours.
V mejah kliničnih odmerkov od 80 do 300 mg/m2 je povprečni plazemski očistek paklitaksela med 13 in 30 l/h/m2, povprečna končna razpolovna doba pa je med 13 in 27 urami.
Powder for dispersion for infusion.
Prašek za disperzijo za infundiranje.
Time (months)
(meseci)
The symptoms were usually transient, typically occurred three days after human serum albumin-paclitaxel nanoparticles administration and resolved within a week.
Simptomi, ki so bili večinoma prehodne narave, so se navadno pojavili tri dni po prejemu paklitaksela, vezanega na nanodelce humanega serumskega albumina, in izginili v enem tednu.
Anaemia (Hb < 10 g/dl) was observed in 46% of patients on human serum albumin-paclitaxel nanoparticles, and was severe (Hb < 8 g/dl) in three cases.
Anemijo (Hb < 10 g/dl) so opazili pri 46 % bolnikov, ki so prejemali paklitaksel, vezanega na nanodelce humanega serumskega albumina; v treh primerih pa je bila huda (Hb < 8 g/dl).
• Pazenir is used in non-small cell lung cancer where surgery or radiotherapy would not be suitable to treat the disease.
• Zdravilo Pazenir se uporablja pri nedrobnoceličnem pljučnem raku, kadar operacija ali obsevanje nista primerna za zdravljenje bolezni.
Each ml of concentrate contains 0.183 mmol sodium, which is 4.2 mg of sodium.
En ml koncentrata vsebuje 0,183 mmol natrija, kar ustreza 4,2 mg natrija.
This resulted in significantly higher exposure to unbound paclitaxel with human serum albumin-paclitaxel nanoparticles compared with solvent-based paclitaxel, even though the total exposure is comparable.
To je povzročilo značilno večjo izpostavljenost nevezanemu paklitakselu s paklitakselom, vezanim na nanodelce humanega serumskega albumina, v primerjavi s paklitakselom na bazi topila, čeprav je bila celotna izpostavljenost primerljiva.
Pazenir is used to treat the following types of cancer:
Zdravilo Pazenir se uporablja za zdravljenje naslednjih vrst raka: Rak dojk
Dose adjustments during treatment of breast cancer
Prilagajanje odmerka med zdravljenjem raka dojk
4.6 Fertility, pregnancy and breast-feeding
4.6 Plodnost, nosečnost in dojenje
The fraction of free paclitaxel was significantly higher with human serum albumin-paclitaxel nanoparticles (6.2%) than with solventbased paclitaxel (2.3%).
Delež prostega paklitaksela je bil značilno višji pri paklitakselu, vezanem na nanodelce humanega serumskega albumina, (6,2 %) kot pri paklitakselu na bazi topila (2,3 %).
The other ingredient is human albumin (containing sodium, sodium caprylate and N-acetyl DL tryptophanate), see section 2 “Pazenir contains sodium”.
Druga sestavina zdravila je humani albumin (ki vsebuje natrij, natrijev kaprilat in N-acetil DL triptofanat), glejte poglavje 2 »Zdravilo Pazenir vsebuje natrij«.
Delay doses until recovery
Odložite odmerjanje do okrevanja
There was no statistically significant difference in progression-free survival (by blinded radiologist assessment) and overall survival between the two treatment arms.
Med obema skupinama zdravljenja ni bilo statistično značilne razlike v preživetju brez napredovanja bolezni (s slepim radiološkim pregledom) in celokupnim preživetjem.
Tell your doctor if you are taking or have recently taken any other medicines.
Obvestite zdravnika, če jemljete, ste pred kratkim jemali katero koli drugo zdravilo, vključno z zdravili brez recepta in zeliščnimi pripravki.
Each ml of Pazenir contains approximately 4.2 mg of sodium.
En ml zdravila Pazenir vsebuje približno 4,2 mg natrija.
Pronounced hair loss ≥50% is expected for the majority of patients who experience alopecia.
se pričakuje pri večini bolnikov, pri katerih se pojavi alopecija.
Patients with pancreatic adenocarcinoma aged 75 years and older should be carefully assessed before treatment is considered (see section 4.4).
Bolnike z adenokarcinomom trebušne slinavke, stare 75 let in več, je treba skrbno oceniti, preden pride v poštev zdravljenje (glejte poglavje 4.4).
Fourteen percent of the patients had not received prior chemotherapy; 27% had received chemotherapy in the adjuvant setting only, 40% in the metastatic setting only, and 19% in both metastatic and adjuvant settings.
Predhodne kemoterapije ni prejemalo 14 % bolnikov, 27 % jih je prejemalo kemoterapijo samo kot dodatno zdravljenje, 40 % samo v metastatskem stanju in 19 % v metastatskem stanju in kot dodatno zdravljenje.
Based on population pharmacokinetic analysis, the total volume of distribution is approximately 1741 L; the large volume of distribution indicates extensive extravascular distribution and/or tissue binding of paclitaxel.
Na podlagi populacijske farmakokinetične analize je celotni volumen porazdelitve približno 1741 l;
• Skin reaction to another agent or lung inflammation following radiation
• kožna reakcija na drugo zdravilo ali vnetje pljuč zaradi obsevanja
Upon intravenous administration, the nanoparticles dissociate rapidly into soluble, albumin bound paclitaxel complexes of approximately 10 nm in size.
Po intravenskem dajanju se nanodelci hitro razkrojijo v topne komplekse paklitaksela, vezanega na albumin, velikosti približno 10 nm.
The European Medicines Agency has waived the obligation to submit the results of studies with human serum albumin-paclitaxel nanoparticles in all subsets of the paediatric population in the treatment of metastatic breast cancer, pancreatic adenocarcinoma and non-small cell lung cancer (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij s paklitakselom, vezanim na nanodelce humanega serumskega albumina, za zdravljenje metastatskega raka dojk, adenokarcinoma trebušne slinavke in nedrobnoceličnega pljučnega raka, za vse podskupine pediatrične populacije (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Treatment should be directed at the major anticipated toxicities, which are bone marrow suppression, mucositis and peripheral neuropathy.
Zdravljenje mora biti usmerjeno glede na večje pričakovane toksične učinke, kot so zavrtje delovanja kostnega mozga, mukozitis in periferna nevropatija.
Paclitaxel clearance is primarily determined by CYP2C8 and CYP3A4 mediated metabolism followed by biliary excretion, while gemcitabine is inactivated by cytidine deaminase followed by urinary excretion.
Očistek paklitaksela določa predvsem presnova s CYP2C8 in CYP3A4, ki ji sledi izločanje z žolčem, medtem ko se gemcitabin inaktivira s citidin-deaminazo, čemur sledi izločanje z urinom.
After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with Pazenir and gemcitabine and promptly initiate appropriate treatment and supportive measures (see section 4.2).
Potem, ko izključite infekcijsko etiologijo in ko postavite diagnozo pnevmonitisa, trajno ukinite zdravljenje z zdravilom Pazenir in gemcitabinom in nemudoma uvedite ustrezno zdravljenje in podporne ukrepe (glejte poglavje 4.2).
Day 15: If Day 8 doses were given without modification:
15. dan: Če so bili odmerki 8. dne dani brez sprememb:
In a repeat dose study with 12 patients receiving human serum albumin-paclitaxel nanoparticles administered intravenously at 260 mg/m2, intrapatient variability in AUC was 19% (range = 3.21%37.70%).
V študiji s ponavljajočimi odmerki z 12 bolniki, ki so prejemali paklitaksel, vezan na nanodelce humanega serumskega albumina, intravensko v odmerku 260 mg/m2, je bila variabilnost AUC med bolniki 19 % (razpon = 3,21 %-37,70 %).
Population pharmacokinetic analyses for human serum albumin-paclitaxel nanoparticles indicate that gender, race (Asian vs. White), and type of solid tumours do not have a clinically important effect on systemic exposure (AUC and Cmax) of paclitaxel.
Analize populacijske farmakokinetike za paklitaksel, vezan na nanodelce humanega serumskega albumina, kažejo, da spol, rasa (azijska proti beli) in vrsta čvrstih tumorjev nimajo klinično pomembnega vpliva na sistemsko izpostavljenost paklitakselu (AUC in Cmax).
Day 15: If Day 8 doses were reduced:
15. dan: Če so bili odmerki 8. dne zmanjšani:
Sixty-four percent of patients had impaired performance status (ECOG 1 or 2) at study entry; 79% had visceral metastases; and 76% had > 3 sites of metastases.
Pri vstopu v raziskavo je imelo 64 % bolnikov zmanjšano telesno zmogljivost (ECOG 1 ali 2), 79 % jih je imelo visceralne metastaze in 76 % jih je imelo > 3 mesta metastaz.
Paclitaxel may cause serious birth defects and should therefore not be used if you are pregnant.
Paklitaksel lahko povzroči hude prirojene okvare, zato ga nosečnice ne smejo jemati.
Animal studies with human serum albumin-paclitaxel nanoparticles showed non-reversible, toxic effects on the male reproductive organs at clinically relevant exposure levels.
Raziskave s paklitakselom, vezanim na nanodelce humanega serumskega albumina, na živalih so pokazale ireverzibilne, toksične učinke na moške reproduktivne organe pri klinično pomembnih stopnjah izpostavljenosti.
• if you are allergic (hypersensitive) to paclitaxel or any of the other ingredients of Pazenir (listed in section 6);
• če ste alergični (preobčutljivi) na paklitaksel ali katero koli sestavino zdravila Pazenir
The effectiveness and safety of human serum albumin-paclitaxel nanoparticles in patients with central nervous system (CNS) metastases has not been established.
Učinkovitost in varnost paklitaksela, vezanega na nanodelce humanega serumskega albumina, pri bolnikih z metastazami v centralnem živčnem sistemu (CŽS) nista bili dokazani.
Common: Hyperbilirubinaemia
Pogosti: hiperbilirubinemija
Because the toxicity of paclitaxel can be increased with hepatic impairment, administration of Pazenir in patients with hepatic impairment should be performed with caution.
Ker jetrna okvara lahko poveča toksičnost paklitaksela, je treba zdravilo Pazenir pri bolnikih z okvaro jeter dajati previdno.
Pharmacokinetic/pharmacodynamic modeling indicates that there is no correlation between hepatic function (as indicated by the baseline albumin or total bilirubin level) and neutropenia after adjusting for human serum albumin-paclitaxel nanoparticles exposure.
Farmakokinetično/farmakodinamično modeliranje kaže, da ni korelacije med delovanjem jeter (na katerega so sklepali iz izhodiščne koncentracije albumina ali koncentracije celokupnega bilirubina) in nevtropenijo po prilagoditvi na izpostavljenost paklitakselu, vezanem na nanodelce humanega serumskega albumina.
Paclitaxel at doses below the human therapeutic dose was associated with low fertility when administered prior and during mating in male and female rats and foetal toxicity in rats.
Paklitaksel v odmerkih, manjših od terapevtskega odmerka pri ljudeh, so povezovali z nizko plodnostjo, kadar so ga dajali samcem in samicam podgan pred parjenjem in med njim, in fetalno toksičnostjo pri podganah.
Ask your doctor for advice before taking this medicine.
Pred jemanjem zdravila se posvetujte z zdravnikom.
General disorders and administration site conditions Asthenia/Fatigue was reported in 40% of the patients.
Splošne težave in spremembe na mestu aplikacije Astenija/utrujenost je bila opažena pri 40 % bolnikov.
In patients aged 75 years and older who received human serum albumin-paclitaxel nanoparticles and gemcitabine, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation (see section 4.4).
Pri bolnikih, starih 75 let in več, ki so prejemali paklitaksel, vezan na nanodelce humanega serumskega albumina, in gemcitabin, je bila večja incidenca resnih neželenih učinkov in neželenih učinkov, ki so povzročili prekinitev zdravljenja (glejte poglavje 4.4).
Pharmacokinetic/pharmacodynamic modelling using data from 125 patients with advanced solid tumours indicates that patients ≥ 65 years of age may be more susceptible to development of neutropenia within the first treatment cycle.
Farmakokinetično/farmakodinamično modeliranje z uporabo podatkov 125 bolnikov z napredovalimi čvrstimi tumorji kaže, da utegnejo biti bolniki, stari 65 let in več, dovzetnejši za nastanek nevtropenije v prvem ciklu zdravljenja.
Pharmacotherapeutic group: Antineoplastic agents, plant alkaloids and other natural products, taxanes, ATC Code: L01CD01
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), rastlinski alkaloidi in druge naravne učinkovine (zaviralci mitoze), taksani, oznaka ATC: L01CD01
Following human serum albumin-paclitaxel nanoparticles administration to patients with solid tumours, paclitaxel is evenly distributed into blood cells and plasma and is highly bound to plasma proteins (94%).
Po dajanju paklitaksela, vezanega na nanodelce humanega serumskega albumina, bolnikom s čvrstimi tumorji se paklitaksel enakomerno porazdeli v krvne celice in plazmo ter je v veliki meri vezan na plazemske beljakovine (94 %).
• if you experience any abnormal bruising, bleeding, or signs of infections such as a sore throat or a fever;
• če se pojavijo kakšne nenormalne modrice, krvavitev ali znaki okužbe, na primer vneto žrelo ali zvišana telesna temperatura;